Andreas Behren

20.6k total citations · 1 hit paper
73 papers, 2.6k citations indexed

About

Andreas Behren is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Andreas Behren has authored 73 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 32 papers in Immunology and 29 papers in Molecular Biology. Recurrent topics in Andreas Behren's work include Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (20 papers) and CAR-T cell therapy research (12 papers). Andreas Behren is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Immunotherapy and Immune Responses (20 papers) and CAR-T cell therapy research (12 papers). Andreas Behren collaborates with scholars based in Australia, United States and Germany. Andreas Behren's co-authors include Jonathan Cebon, Matt Trau, Yuling Wang, Alexander Dobrovic, Matthew Anaka, Jing Wang, Alain Wuethrich, Christopher Hudson, Abu Ali Ibn Sina and Simon Chang‐Hao Tsao and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Andreas Behren

72 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A gut microbial signature for combination immune checkpoint blockade across cancer types

2024 67 citations Ashray Gunjur, Yan Shao et al. Nature Medicine profile →

Peers

Countries citing papers authored by Andreas Behren

Since Specialization

Citations

This map shows the geographic impact of Andreas Behren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Behren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Behren more than expected).

Fields of papers citing papers by Andreas Behren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Behren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Behren. The network helps show where Andreas Behren may publish in the future.

Co-authorship network of co-authors of Andreas Behren

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Behren. A scholar is included among the top collaborators of Andreas Behren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Behren. Andreas Behren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Case report: Partial regression of metastatic squamous cell carcinoma with altered azathioprine dosage after long-term use in renal transplant patient 2024 ·Frontiers in Immunology ·(unknown), Jessica Da Gama Duarte, (unknown), Louise Jackett, John Whitlam, Andreas Behren, David Gyorki	0
2	A gut microbial signature for combination immune checkpoint blockade across cancer types breakdown → 2024 ·Nature Medicine ·Ashray Gunjur, Yan Shao, (unknown), Oliver Klein, Andre Mu, Bastiaan W. Haak, Ben Markman, Damien Kee, Matteo S. Carlino, Craig Underhill, Sophia Frentzas, Michael Michael, Bo Gao, Jodie Palmer, Jonathan Cebon, Andreas Behren, David J. Adams, Trevor D. Lawley	67
3	A Microfluidic Liquid Biopsy Platform to Monitor Protein Biomarker Heterogeneity in Single Circulating Therapy‐Resistance Cancer Cell 2023 ·SHILAP Revista de lepidopterología ·Emtiaz Ahmed, (unknown), Junrong Li, Andreas Behren, Richard J. Lobb, Andreas Möller, Alain Wuethrich, Shuvashis Dey, Abu Ali Ibn Sina, Matt Trau	3
4	A multispectral immunohistochemistry panel to investigate γδ T cells and butyrophilin molecules in the tumour microenvironment 2022 ·SHILAP Revista de lepidopterología ·Jessica Da Gama Duarte, (unknown), (unknown), Simone Ostrouska, Andreas Behren	1
5	‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors 2022 ·The Journal of Pathology ·Ashray Gunjur, (unknown), Oliver Klein, Andreas Behren, Trevor D. Lawley, Sarah J. Welsh, David J. Adams	10
6	Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies 2021 ·International Journal of Molecular Sciences ·Jessica Da Gama Duarte, (unknown), Anna R. Young, Masaru Hayashi, (unknown), Andreas L. Lopata, (unknown), Mikio Mikami, Andreas Behren, Els Meeusen	1
7	In Situ Single Cell Proteomics Reveals Circulating Tumor Cell Heterogeneity during Treatment 2021 ·ACS Nano ·Kamil Reza Khondakar, Shuvashis Dey, Alain Wuethrich, Jing Wang, Andreas Behren, Fiach Antaw, Yuling Wang, Abu Ali Ibn Sina, Matt Trau	73
8	Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma 2020 ·Science Advances ·Jing Wang, Alain Wuethrich, Abu Ali Ibn Sina, Rebecca E. Lane, Lynlee L. Lin, Yuling Wang, Jonathan Cebon, Andreas Behren, Matt Trau	131
9	Methylation dependent gold adsorption behaviour identifies cancer derived extracellular vesicular DNA 2020 ·Nanoscale Horizons ·Abu Ali Ibn Sina, (unknown), Ramanathan Vaidyanathan, (unknown), Shuvashis Dey, Jing Wang, Andreas Behren, Alain Wuethrich, Laura G. Carrascosa, Matt Trau	8
10	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma 2020 ·Cancer Immunology Research ·Pouya Faridi, Katherine Woods, Simone Ostrouska, (unknown), (unknown), (unknown), Stephen Q. Wong, Weisan Chen, Sri H. Ramarathinam, Terry C.C. Lim Kam Sian, Nathan P. Croft, Chen Li, Rochelle Ayala, Jonathan Cebon, Anthony W. Purcell, Ralf B. Schittenhelm, Andreas Behren	41
11	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers 2020 ·Clinical Cancer Research ·Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare L. Scott, Adnan Nagrial, Andreas Behren, (unknown), Jodie Palmer, Jonathan Cebon	116
12	Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes 2020 ·Scientific Reports ·Prashanth Prithviraj, Matthew Anaka, Erik W. Thompson, (unknown), Marzena Walkiewicz, Candani Tutuka, Andreas Behren, George Kannourakis, Aparna Jayachandran	7
13	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p> 2020 ·Drug Design Development and Therapy ·Jason D. Lickliter, Hui Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao, Adnan Nagrial, Peter Grimison, (unknown), Jianjun Zou, Lianshan Zhang, (unknown), Michael Lahn, Howard Kallender, (unknown), (unknown), Katherine Woods, Andreas Behren, Pablo Fernández‐Peñas, Michael Millward, Tarek Meniawy	26
14	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival 2019 ·Cell Death and Disease ·Erinna F. Lee, Tiffany J. Harris, Sharon Tran, Marco Evangelista, Surein Arulananda, Thomas John, (unknown), (unknown), Haoran Zhu, Gency Gunasingh, David Segal, Andreas Behren, Jonathan Cebon, Alexander Dobrovic, John M. Mariadason, Andreas Strasser, Leona Rohrbeck, Nikolas K. Haass, Marco J. Herold, W. Douglas Fairlie	142
15	A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response 2019 ·Journal of Investigative Dermatology ·Heloise M. Halse, Franco Caramia, Catriona McLean, Minyu Wang, Han Xian Aw Yeang, Simon P. Keam, Andreas Behren, (unknown), Martin Haskett, Jonathan Cebon, Grant A. McArthur, Paul J. Neeson, Victoria Mar	8
16	Accumulation of CD103⁺ CD8⁺ T cells in a cutaneous melanoma micrometastasis 2019 ·Clinical & Translational Immunology ·Katharina Hochheiser, Han Xian Aw Yeang, Teagan Wagner, Candani Tutuka, Andreas Behren, Jason Waithman, Christopher Angel, Paul J. Neeson, Thomas Gebhardt, David Gyorki	8
17	Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma 2018 ·Scientific Reports ·Heloise M. Halse, Andrew J. Colebatch, Pasquale Petrone, Melissa A. Henderson, Jane K. Mills, Hayden Snow, Jennifer A. Westwood, Shahneen Sandhu, Jeanette Raleigh, Andreas Behren, Jonathan Cebon, Phillip K. Darcy, Michael H. Kershaw, Grant A. McArthur, David Gyorki, Paul J. Neeson	74
18	Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity 2016 ·Cancer Immunology Research ·Jun Yao, Otávia L. Caballero, Ying Huang, Calvin Lin, Donata Rimoldi, Andreas Behren, Jonathan Cebon, Mien‐Chie Hung, John N. Weinstein, Robert L. Strausberg, Qi Zhao	49
19	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma 2015 ·Clinical Cancer Research ·Miles C. Andrews, Natalie Turner, (unknown), Andrew W. Roberts, Andrew Grigg, Andreas Behren, Jonathan Cebon	3
20	BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage 2013 ·Clinical Cancer Research ·Victoria Mar, Stephen Q. Wong, Jason Li, Richard A. Scolyer, Catriona McLean, Anthony T. Papenfuss, Richard W. Tothill, Hojabr Kakavand, Graham J. Mann, John F. Thompson, Andreas Behren, Jonathan Cebon, Rory Wolfe, John W. Kelly, Alexander Dobrovic, Grant A. McArthur	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact